Director of Cancer Center
Hong Jae Chon, MD, PhD, is Professor of Medical Oncology at CHA University School of Medicine and Director of the Cancer Center at CHA Bundang Medical Center, Republic of Korea.
He is the principal investigator of multiple clinical trials evaluating novel systemic therapies and immunotherapy-based combination strategies for hepatocellular carcinoma (HCC). He is also actively involved in the early-phase clinical development of novel anticancer agents and international multicenter clinical trials.
His clinical and translational research focuses on cancer immunotherapy, predictive biomarkers, and the tumor microenvironment, with the aim of improving outcomes for patients with HCC. He has authored more than 130 peer-reviewed publications in leading international journals, including The Lancet, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Journal of Hepatology, and Hepatology.
He is a member of the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). He also serves on committees of the International Liver Cancer Association (ILCA) and the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) 2027.
Eisai, Roche, ONO, MSD, Bristol Myers Squibb, BeOne Medicines, Sanofi, Servier, AstraZeneca, Boryung, and Chugai; has served as a consultant or advisory board member for Eisai, Roche, ONO, MSD, Bristol Myers Squibb, BeOne Medicines, Servier, AstraZeneca, Boryung, IMBDx, Aptamer Science, and Bayer; and has received research grants from Roche, BeOne Medicines, IMBDx, Dong-A ST, Boryung, Medivir, Guardant Health, Servier, and Handok. He has also received travel, accommodation, or expense support from Medivir and Chugai.
Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers